This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Subgroup Analyses Of Pivotal And Open Label Prevention Trials Showed Effectiveness Of ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) In Prevention Of Angioedema Attacks In Patients With Hereditary Angioedema (HAE) Poorly Controlled On Anabolic Androgens

Lead author Bruce L. Zuraw, Professor of Medicine, Chief of the Section of Allergy and Immunology, and Director of the Allergy and Immunology Training Program at the University of California School of Medicine, San Diego delivered these findings during an oral platform presentation at the 8 th C1 Inhibitor Deficiency Workshop in Budapest, Hungary.

"While clinical trials have demonstrated the efficacy and safety of Cinryze for the long-term prevention of HAE, these data demonstrate that Cinryze is an important option, even in patients who have been managed on anabolic androgens and continue to experience multiple attacks of HAE,"  said Dr. Zuraw. "It reinforces current evidence based guidelines for the management of HAE, especially given the long-term risk/benefit of anabolic androgens."

The abstract 'Anabolic androgen experience and response to CINRYZE (C1 esterase inhibitor [human]) in the prevention trials in patients with HAE' will be published in the May edition of The Journal of Angioedema.

About Cinryze ® (C1 esterase inhibitor [human]) Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.  In the U.S., Cinryze is approved by the FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  In the E.U., the product is approved by the EMA for the treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment. Cinryze is for intravenous use only.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration. 

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,530.95 -152.63 -0.86%
S&P 500 2,044.40 -24.36 -1.18%
NASDAQ 4,903.4790 -88.4610 -1.77%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs